CIPLA

Cipla Share Price

₹1,475.85 -0.2 (-0.01%)

24 Dec, 2024 09:15

SIP TrendupStart SIP in CIPLA

Start SIP

Performance

  • Low
  • ₹1,462
  • High
  • ₹1,476
  • 52 Week Low
  • ₹1,232
  • 52 Week High
  • ₹1,702
  • Open Price₹1,476
  • Previous Close₹1,476
  • Volume29,405

Investment Returns

  • Over 1 Month -0.7%
  • Over 3 Month -10.98%
  • Over 6 Month -4.25%
  • Over 1 Year + 19.46%
SIP Lightning

Smart Investing Starts Here Start SIP with Cipla for Steady Growth!

Invest Now

Cipla Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 26.6
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 119,192
  • P/B Ratio
  • 4.4
  • Average True Range
  • 34.81
  • EPS
  • 57.16
  • Dividend Yield
  • 0.9
  • MACD Signal
  • -17.04
  • RSI
  • 47.06
  • MFI
  • 30.77

Cipla Financials

Cipla Technicals

EMA & SMA

Current Price
₹1,475.85
-0.2 (-0.01%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹1,480.93
  • 50 Day
  • ₹1,510.48
  • 100 Day
  • ₹1,524.40
  • 200 Day
  • ₹1,487.74

Resistance and Support

1475.28 Pivot Speed
  • R3 1,523.97
  • R2 1,507.48
  • R1 1,491.77
  • S1 1,459.57
  • S2 1,443.08
  • S3 1,427.37

What's your outlook on Cipla?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Cipla Ltd., is a global pharmaceutical leader, committed to "Caring for Life." With a presence in 80+ countries, Cipla offers over 1,500 products across various therapeutic categories, focusing on making healthcare affordable and accessible worldwide.

Cipla has an operating revenue of Rs. 26,512.01 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 22% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 48 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Cipla Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-29 Quarterly Results
2024-07-26 Quarterly Results
2024-05-10 Audited Results & Final Dividend
2024-01-22 Quarterly Results (Revised) per share(50%)Special Dividend
2023-10-27 Quarterly Results
Date Purpose Remarks
2024-08-02 FINAL Rs.13.00 per share(650%)Final Dividend
2023-07-21 FINAL Rs.8.50 per share(425%)Final Dividend
2022-08-10 FINAL Rs.5.00 per share(250%)Dividend

Cipla F&O

Cipla Shareholding Pattern

30.92%
17.48%
4.67%
28.8%
0.12%
14.16%
3.85%

About Cipla

Cipla Ltd. is a pharmaceutical company in India with a strong global presence. With operations in 80 countries and 47 manufacturing facilities, it sells 1500 products in the market. The largest market of Cipla Ltd. is India, followed by Africa and North America.

The product profile of Cipla Ltd. ranges from drugs in the respiratory, pediatric asthma, nebulisation, anti-retroviral, urology, cardiology, anti-infective, CNS, and several other illnesses and disorders. Cipla's business is divided into three units - Generics and Branded Generics, Specialty and Consumer Health. 

The Generics and Branded Generics unit contributes around 19% of the pharmaceutical revenues in India. The division has 4,000+ partners covering the entire country and is constantly seeking to expand the product portfolio.

The Specialty unit focuses on speciality medicines in respiratory, CNS and critical care. This unit's operations are run under Cipla Technologies LLC (CipTec) and have its headquarters in San Diego, California. 

The Consumer Health Segment focuses on simplifying healthcare and offering simple and over-the-counter solutions to the consumers. A few brands under this business unit are Nicotex, ActivKids ImmunoBoosters, Cofsils, and UnoBiotics.

Cipla was founded in 1935 in Mumbai as Chemical Industrial & Pharmaceutical Laboratories Ltd. by Khwaja Abdul Hamied. The name of the company was changed to Cipla in 1984. It received a major boost in 1985 when the US FDA approved its bulk drug facility. Cipla went on to launch the world's first oral iron chelator in 1995. 

The company acquired the South African company Cipla-Medproin in 2013 and entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa in 2019.

In September 2021, Cipla Ltd. subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation. It is a not-for-profit organisation focused on building digital healthcare infrastructure.

Shareholding Pattern

A total of 230 mutual funds invest in Cipla Ltd., with a total holding of 13.91%. The number of FIIs and FPIs that have invested in it is 786, and their total holding amount to 26.64. These figures are as of March 2022.

The top mutual funds that have invested in Cipla Ltd. are SBI ETF Nifty 50, Baroda BNP Paribas Balanced Advantage Fund Regular Growth, Mirae Asset Healthcare Fund Regular Growth, Franklin India Bluechip Fund-Growth and UTI Nifty ETF.

View More
  • NSE Symbol
  • CIPLA
  • BSE Symbol
  • 500087
  • Managing Director & Global CEO
  • Mr. Umang Vohra
  • ISIN
  • INE059A01026

Similar Stocks to Cipla

Cipla FAQs

Cipla share price is ₹1,475 As on 24 December, 2024 | 09:01

The Market Cap of Cipla is ₹119191.7 Cr As on 24 December, 2024 | 09:01

The P/E ratio of Cipla is 26.6 As on 24 December, 2024 | 09:01

The PB ratio of Cipla is 4.4 As on 24 December, 2024 | 09:01

Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.

Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.

Umang Vohra has been the CEO of Cipla since 1 September 2016.

Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.

You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23